Cargando…

In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA)

Purpose: The most aggressive form of skin cancer is the malignant melanoma. Because of its high metastatic potential the early detection of primary melanoma tumors and metastases using non-invasive PET imaging determines the outcome of the disease. Previous studies have already shown that benzamide...

Descripción completa

Detalles Bibliográficos
Autores principales: Kertész, István, Vida, András, Nagy, Gábor, Emri, Miklós, Farkas, Antal, Kis, Adrienn, Angyal, János, Dénes, Noémi, Szabó, Judit P., Kovács, Tünde, Bai, Péter, Trencsényi, György
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381165/
https://www.ncbi.nlm.nih.gov/pubmed/28382139
http://dx.doi.org/10.7150/jca.17550
_version_ 1782519884736888832
author Kertész, István
Vida, András
Nagy, Gábor
Emri, Miklós
Farkas, Antal
Kis, Adrienn
Angyal, János
Dénes, Noémi
Szabó, Judit P.
Kovács, Tünde
Bai, Péter
Trencsényi, György
author_facet Kertész, István
Vida, András
Nagy, Gábor
Emri, Miklós
Farkas, Antal
Kis, Adrienn
Angyal, János
Dénes, Noémi
Szabó, Judit P.
Kovács, Tünde
Bai, Péter
Trencsényi, György
author_sort Kertész, István
collection PubMed
description Purpose: The most aggressive form of skin cancer is the malignant melanoma. Because of its high metastatic potential the early detection of primary melanoma tumors and metastases using non-invasive PET imaging determines the outcome of the disease. Previous studies have already shown that benzamide derivatives, such as procainamide (PCA) specifically bind to melanin pigment. The aim of this study was to synthesize and investigate the melanin specificity of the novel (68)Ga-labeled NODAGA-PCA molecule in vitro and in vivo using PET techniques. Methods: Procainamide (PCA) was conjugated with NODAGA chelator and was labeled with Ga-68 ((68)Ga-NODAGA-PCA). The melanin specificity of (68)Ga-NODAGA-PCA was tested in vitro, ex vivo and in vivo using melanotic B16-F10 and amelanotic Melur melanoma cell lines. By subcutaneous and intravenous injection of melanoma cells tumor-bearing mice were prepared, on which biodistribution studies and small animal PET/CT scans were performed for (68)Ga-NODAGA-PCA and (18)FDG tracers. Results: (68)Ga-NODAGA-PCA was produced with high specific activity (14.9±3.9 GBq/µmol) and with excellent radiochemical purity (98%<), at all cases. In vitro experiments showed that (68)Ga-NODAGA-PCA uptake of B16-F10 cells was significantly (p≤0.01) higher than Melur cells. Ex vivo biodistribution and in vivo PET/CT studies using subcutaneous and metastatic tumor models showed significantly (p≤0.01) higher (68)Ga-NODAGA-PCA uptake in B16-F10 primary tumors and lung metastases in comparison with amelanotic Melur tumors. In experiments where (18)FDG and (68)Ga-NODAGA-PCA uptake of B16-F10 tumors was compared, we found that the tumor-to-muscle (T/M) and tumor-to-lung (T/L) ratios were significantly (p≤0.05 and p≤0.01) higher using (68)Ga-NODAGA-PCA than the (18)FDG accumulation. Conclusion: Our novel radiotracer (68)Ga-NODAGA-PCA showed specific binding to the melanin producing experimental melanoma tumors. Therefore, (68)Ga-NODAGA-PCA is a suitable diagnostic radiotracer for the detection of melanoma tumors and metastases in vivo.
format Online
Article
Text
id pubmed-5381165
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-53811652017-04-05 In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA) Kertész, István Vida, András Nagy, Gábor Emri, Miklós Farkas, Antal Kis, Adrienn Angyal, János Dénes, Noémi Szabó, Judit P. Kovács, Tünde Bai, Péter Trencsényi, György J Cancer Research Paper Purpose: The most aggressive form of skin cancer is the malignant melanoma. Because of its high metastatic potential the early detection of primary melanoma tumors and metastases using non-invasive PET imaging determines the outcome of the disease. Previous studies have already shown that benzamide derivatives, such as procainamide (PCA) specifically bind to melanin pigment. The aim of this study was to synthesize and investigate the melanin specificity of the novel (68)Ga-labeled NODAGA-PCA molecule in vitro and in vivo using PET techniques. Methods: Procainamide (PCA) was conjugated with NODAGA chelator and was labeled with Ga-68 ((68)Ga-NODAGA-PCA). The melanin specificity of (68)Ga-NODAGA-PCA was tested in vitro, ex vivo and in vivo using melanotic B16-F10 and amelanotic Melur melanoma cell lines. By subcutaneous and intravenous injection of melanoma cells tumor-bearing mice were prepared, on which biodistribution studies and small animal PET/CT scans were performed for (68)Ga-NODAGA-PCA and (18)FDG tracers. Results: (68)Ga-NODAGA-PCA was produced with high specific activity (14.9±3.9 GBq/µmol) and with excellent radiochemical purity (98%<), at all cases. In vitro experiments showed that (68)Ga-NODAGA-PCA uptake of B16-F10 cells was significantly (p≤0.01) higher than Melur cells. Ex vivo biodistribution and in vivo PET/CT studies using subcutaneous and metastatic tumor models showed significantly (p≤0.01) higher (68)Ga-NODAGA-PCA uptake in B16-F10 primary tumors and lung metastases in comparison with amelanotic Melur tumors. In experiments where (18)FDG and (68)Ga-NODAGA-PCA uptake of B16-F10 tumors was compared, we found that the tumor-to-muscle (T/M) and tumor-to-lung (T/L) ratios were significantly (p≤0.05 and p≤0.01) higher using (68)Ga-NODAGA-PCA than the (18)FDG accumulation. Conclusion: Our novel radiotracer (68)Ga-NODAGA-PCA showed specific binding to the melanin producing experimental melanoma tumors. Therefore, (68)Ga-NODAGA-PCA is a suitable diagnostic radiotracer for the detection of melanoma tumors and metastases in vivo. Ivyspring International Publisher 2017-02-25 /pmc/articles/PMC5381165/ /pubmed/28382139 http://dx.doi.org/10.7150/jca.17550 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Kertész, István
Vida, András
Nagy, Gábor
Emri, Miklós
Farkas, Antal
Kis, Adrienn
Angyal, János
Dénes, Noémi
Szabó, Judit P.
Kovács, Tünde
Bai, Péter
Trencsényi, György
In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA)
title In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA)
title_full In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA)
title_fullStr In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA)
title_full_unstemmed In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA)
title_short In Vivo Imaging of Experimental Melanoma Tumors using the Novel Radiotracer (68)Ga-NODAGA-Procainamide (PCA)
title_sort in vivo imaging of experimental melanoma tumors using the novel radiotracer (68)ga-nodaga-procainamide (pca)
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381165/
https://www.ncbi.nlm.nih.gov/pubmed/28382139
http://dx.doi.org/10.7150/jca.17550
work_keys_str_mv AT kerteszistvan invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT vidaandras invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT nagygabor invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT emrimiklos invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT farkasantal invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT kisadrienn invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT angyaljanos invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT denesnoemi invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT szabojuditp invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT kovacstunde invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT baipeter invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca
AT trencsenyigyorgy invivoimagingofexperimentalmelanomatumorsusingthenovelradiotracer68ganodagaprocainamidepca